"Orange Book" Patent Abuses Could Be Addressed By FDA Limitations - Atty.

This article was originally published in The Tan Sheet

07 Jun 1999
News

The Tan Sheet

Executive Summary

FDA should issue regulations limiting "Orange Book" patent listings by brand name pharmaceutical companies to those patents that claim the listed drug or approved method of use, attorney David Weeda suggested at the Warburg Dillon Read Specialty Pharmaceutical Conference in New York City May 26. Weeda, a partner at the D.C. firm Olsson, Frank and Weeda, is a former FDA associate chief counsel.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
Consumer
Subjects
OTC Drugs

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Consumer OTC Drugs

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS089904

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS089904

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

"Orange Book" Patent Abuses Could Be Addressed By FDA Limitations - Atty.

News

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert